Thu, Sep 18, 2014, 12:00 AM EDT - U.S. Markets open in 9 hrs 30 mins

Recent

% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, Inc. Message Board

  • maximus06906 maximus06906 Jan 11, 2013 11:07 AM Flag

    Seeking Alpha Article Yesterday

    Normally not a fan of the SA articles but yesterday's article was well done. Person put some time and thought into it and really made the case for the upside for SGI-110. Recommend reading the article.

    Max

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Hey Max, you took the words right pout of my mouth. Seeking Alpha is kind of like a cheerleaders site but sometimes they do some inciteful analysis. This was one of those times.

      I really like their analysis of the potential (non) losses from Dacogen going off patent. It supports nearly everything that we have read on this message board over the last 12 to 18 months. If generic Vidaza is not on the market 18 months after patent expiration (second rated) Dacogen should seem reletively safe.

      I love the fact that the phase two portion of the two stage SGI110 trial is in progress and a second trial is also getting underway. It is still too early to call, but hope continues to bloom that SGI110 is the real deal.

      I would love to see more articles like this, especially from some of the better known analysts.

    • Max,

      Same sentiment here. Very solidly written indeed.

      I believe it's possible to see clear skies (a magnitude of 52/wk highs) if he can use this recent momentum to push through the $3.50 barrier.

      We got rocked when we discontinued the early phase project along with the IBB's near 20/point correction. Both occurred as we were pushing new highs, simply bad timing.

      It's time to retest them.

      Sentiment: Buy

 
ASTX
8.4950.000(0.00%)Oct 10 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.